Market Signal Briefing

BlackRock's global head of digital assets, Robbie Mitchnick, believes the institutional adoption of crypto exchange-traded funds is still in its early stages. During a Sept.

Sui price is testing support at $3.10 as rising trading volume and new partnerships hint at long-term strength.

Summary

SUI trades at $3.13, down 18% weekly, with $1.66B spot volume up 46% in 24h.
Futures volume rises 23% to $7.48B while open interest falls 4.4%, showing cautious positioning.
New deals with t’order, CUDIS Wellness, and Google AI highlight institutional and real-world adoption.

Sui is trading at $3.13 at press time, down 3.5% in the past 24 hours, as the token approaches key support levels. Over the past week, it has dropped 18%, while in the past 30 days, it is still down 10%.

Daily trading activity shows a surge in market interest, with $1.66 billion in spot volume recorded in the last 24 hours, a 45.9% jump compared to the previous day. On the derivatives side, CoinGlass data shows that Sui’s (SUI) open interest fell 4.4% to $1.69 billion, while futures volume rose 23% to $7.48 billion.

This combination implies that although traders are engaging more actively, many are closing out positions rather than opening new ones.

New partnerships drive long-term use cases
Despite the near-term pullback, Sui continues to expand its ecosystem with major partnerships that strengthen its institutional and real-world presence.

On Sept. 24, Sui announced a partnership with t’order, the leading table-ordering platform in South Korea, T’order processes $4.3 billion annually and serves 35 million users. Using Sui’s sub-0.5-second transaction speeds and Walrus storage for safe loyalty data, the partnership integrates a KRW-pegged stablecoin across 300,000 point-of-sale devices.

A day later, Sui partnered with CUDIS Wellness to bring AI-powered smart rings and health data management onchain. Through Walrus and SEAL, users will own and monetize encrypted biometric data, aligning Sui with the growing wellness sector.

Sui and Google AI also partnered to introduce the Agentic Payments Protocol earlier this month. This system opens up new use cases in DeFi, IoT, and enterprise automation by enabling AI agents to make payments on their own.

Sui price technical analysis
On the daily chart, SUI is trading close to the lower Bollinger band at $3.13, indicating oversold conditions. The relative strength index at 38 is near the oversold zone, while the Stochastic RSI and Williams %R both indicate possible buy conditions.

Sui daily chart. Credit: crypto.news
All of the major SMAs and EMAs, from the 10-day ($3.38) to the 200-day ($3.20), flash sell signals, a bearish sign. Momentum and MACD indicators also lean bearish, showing the trend is still weak.

In the short term, holding above $3.10 support is critical. The $2.90–$3.00 range might be the next target if there is a breakdown. On the upside, the first indication of a potential rebound would be the recovery of the 20-day SMA around $3.46.

, /PRNewswire/ -- Boeing [NYSE: BA] and Norwegian Group announced today that the airline group has placed an order for 30 737-8 airplanes as the airline looks to expand its service across Europe.

The agreement represents the group's first direct Boeing order since 2017 and increases their 737 MAX order book to 80 airplanes.

"This milestone aircraft order is on attractive terms and secures our fleet growth in a way that supports our planned growth and sustainability targets. By exercising the options and adjusting the delivery profile, we maintain flexibility while reinforcing our commitment to operating one of the most modern and fuel-efficient fleets in Europe," said Geir Karlsen, CEO of Norwegian. "These aircraft will not only lower emissions but also provide our customers with an even better travel experience. We are pleased to extend our solid long-term partnership with Boeing through this order."

Norwegian has predominantly operated Boeing single-aisle airplanes since placing its first order for the Next-Generation 737-800 in 2007. It was the first European airline to take delivery of the 737 MAX in 2017 and was also the first airline to operate the 737-8 model on transatlantic routes between Europe and the U.S.

In 2022, Norwegian restructured its order book, firming its commitment to 50 737-8s with options for an additional 30 airplanes.

"Norwegian's impressive performance over the past few years has demonstrated the strength of their network, business model and strategy. Today's agreement for an additional 30 737-8s will support their ambition to be the airline of choice in Scandinavia, providing flexibility to expand across Europe and beyond," said Brad McMullen, Boeing senior vice president of Commercial Sales and Marketing. "Norwegian has been a great partner to the 737 program, having placed over 200 orders for the 737 NG and MAX since 2007. We are honored that Norwegian continues to place its trust in our 737 team to grow its business."

The 737-8 model can carry up to 200 passengers depending on configuration, with a range of up to 3,500 nautical miles (6,480 km). The 737 MAX family is well-suited to support airline fleet modernization by reducing fuel use and carbon emissions by 20% compared to the airplanes they replace.

About Norwegian 
The Norwegian group is a leading Nordic aviation company, headquartered at Fornebu outside Oslo, Norway. The company has over 8,200 employees and owns two of the prominent airlines in the Nordics: Norwegian Air Shuttle and Widerøe's Flyveselskap. Widerøe was acquired by Norwegian in 2024, aiming to facilitate seamless air travel across the two airline's networks.

Norwegian Air Shuttle, the largest Norwegian airline with around 4,700 employees, operates an extensive route network connecting Nordic countries to key European destinations. In 2024, Norwegian carried 22,6 million passengers and maintained a fleet of 86 Boeing 737-800 and 737 MAX 8 aircraft.

About Boeing
As a leading global aerospace company, Boeing develops, manufactures and services commercial airplanes, defense products and space systems for customers in more than 150 countries. As a top U.S. exporter, the company leverages the talents of a global supplier base to advance economic opportunity, sustainability and community impact. Boeing's diverse team is committed to innovating for the future and living the company's core values of safety, quality and integrity. Learn more at www.boeing.com.

Contact:
Boeing Media Relations
[email protected]

SOURCE Boeing

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Rivian looks increasingly like it will be a successful EV start-up, but don't get overexcited by the Tesla similarities.

After Tesla (TSLA -4.29%) proved that a start-up electric car company could take on the traditional automakers, Wall Street jumped into action. That was when Rivian (RIVN -0.44%) came public, to much fanfare. Fast forward a few years to the current day, and Rivian's stock price has fallen some 90% from its all-time highs. Is this a diamond in the rough that could turn you into a millionaire in a Tesla-style success story, or should you have more modest expectations?

Rivian has done big things
To give credit where credit is due, Rivian has achieved a huge amount of success in a very short period of time. It basically went from an idea -- making electric vehicles (EVs) -- to an operating business with a well-respected EV truck and an EV delivery van used widely by retail powerhouse Amazon (AMZN -0.84%). That isn't something that could have been achieved if Rivian didn't have its act together.

Image source: Rivian.

Notably, in late 2024, Rivian hit a key milestone, achieving a modest gross profit for the first time. While a gross profit only means that it was able to generate more revenue from selling its vehicles than it cost to produce them, that is a key step toward positive earnings.

The modest gross profit came after Rivian hit another important goal, scaled production. It delivered more than 10,000 vehicles in the second quarter of 2025, which is a substantial number. It also has a new truck called the R2 coming out next year, which will be geared to the mass market. That should help to further increase volume, which will allow Rivian to spread its costs over even more vehicles.

In many ways, Rivian is following in Tesla's footsteps. Given the massive stock price advance Tesla has made over its history, some investors might see Rivian as a second chance to catch a little of the Tesla opportunity they might have missed. Don't get overly excited.

Rivian has a long way to go
With a well-respected product and key partners like tech giant Amazon and automaker Volkswagen (which has agreed to provide fresh capital to Rivian based on Rivian's ability to meet certain business goals), Rivian seems like it will establish itself as a sustainably profitable business. However, this goal is still likely to be at least a few years away, given the need to invest in the business and research and development right now. Rivian could help you reach a seven-figure net worth, but it isn't likely to do so quickly.

Moreover, the competition set today is much larger than it was when Tesla entered the auto market. At the time, Tesla was basically the only company making EVs. Today, there are a number of sizable EV makers. Virtually all of the traditional automakers are in the space, too. Even if Rivian is successful, it could still just produce a modest profit at the bottom of its income statement, thanks to the changed competitive landscape.

That said, even that outcome would require strong execution. Although Rivian has lived up to its goals, for the most part, so far, there's no guarantee that it will continue to do so in the future. If the company starts missing its targets, investors are likely to turn deeply negative on the stock.

How much more negative could they get after a 90% price decline? Well, the stock happens to be up nearly 23% over the past year, which is notably better than the nearly 17% gain of the S&P 500 index (^GSPC -0.50%). Even after a 90%+ decline, there's still ample room for a deep drawdown, as investors appear to have priced in a lot of good news in recent days.

Risk takers may find it attractive
It probably wouldn't be a great idea to bet your house on Rivian. But it has achieved a great deal in a short period of time, with material opportunity for more success in the future. The problem is that it could also fall short of its goals and flame out, like many upstart EV makers have already done. If you see the execution strength and want to add Rivian to a diversified portfolio, it could help you reach millionaire status. Just go in recognizing the risk, which is material, and the time period you need to consider, which is long.

That's why more conservative investors will probably want to sit on the sidelines for now. It makes a great deal of sense to wait at least until the R2 has been brought to market, so investors can assess how well the new car does with consumers.

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon and Tesla. The Motley Fool recommends Volkswagen Ag. The Motley Fool has a disclosure policy.

You don't need to be a billionaire to invest like Buffett.

Legendary investor Warren Buffett is in the final year of leading his mighty conglomerate, Berkshire Hathaway (BRK.A -0.04%) (BRK.B -0.27%). The Oracle of Omaha, now 95, plans to retire at the end of the year following a 60-year run that turned a downtrodden textile company into a hugely successful company valued at more than $1 trillion.

Buffett's investing principles are comparatively simple, but not many have been able to duplicate them. He believes in buying stock in companies with outstanding management, a great position in their industry, solid revenue and earnings, and often, a generous dividend. By buying dividend stocks in companies that pay investors to hold them, Buffett and Berkshire Hathaway have been able to build wealth even faster.

Berkshire Hathaway has long-term investments in dozens of companies, but three stand out right now as ideal companies for anyone wanting to start a buy-and-hold portfolio. And you don't have to be a billionaire to invest like Buffett -- you need less than $300 total to get a share of Bank of America (BAC 0.26%), Chevron (CVX 0.97%), and Kroger (KR -0.06%).

Image source: The Motley Fool.

Bank of America: Buffett's favorite bank stock
Buffett and Berkshire Hathaway have positions in several financial companies. Berkshire owns insurance companies Geico, General Re, and Berkshire Hathaway; stock in credit card companies American Express, Visa, and Mastercard; a stake in the the credit ratings and analytics company Moody's; and a small percentage of Jefferies Financial Group, the investment bank.

But Bank of America is by far the company's biggest bank stock, as Berkshire holds 605.2 million shares for a $31.3 billion stake. Bank of America makes up 10% of Berkshire's entire portfolio. The North Carolina–based financial institution has about 69 million customers and maintains 3,700 locations across the country, as well as a network of 15,000 ATMs and a robust digital presence.

The company has benefited from a period of elevated interest rates that brought in increased net interest income -- the company reported $14.7 billion in net interest income in the second quarter, up 7% from a year ago. And while the Federal Reserve is now starting to lower rates, Bank of America will still be just fine as people begin to take out new loans or refinance mortgages.

Bank of America is also attractive for its 15.2 price-to-earnings ratio and its 2.1% dividend yield.

Chevron: The energy powerhouse
Buffett and Berkshire Hathaway recognize the importance of energy and fossil fuels in today's economy, and the conglomerate has sizable investments in ExxonMobil, Chevron, and Occidental Petroleum.

I like Chevron here. Even though oil prices have been down this year, Chevron still generates a massive amount of free cash flow -- $4.9 billion in the second quarter, up from $2.3 billion a year ago.

The company recently completed its $55 billion acquisition of Hess, emerging victorious over ExxonMobil in a legal battle that saw it win access to the Guyana Stabroek Block that is purportedly the biggest oil discovery in decades with more than 11 billion barrels of oil.

Chevron already recorded record production in the second quarter for the Permian Basin, with 1 billion barrels of oil per day, and I expect production to increase following the Hess merger.

The company pays a generous dividend yield of 4.4%.

Kroger: The defensive pick
Even when spending tightens up and consumer confidence falls, people still need to eat. While consumer discretionary stocks can come under pressure, consumer staples stocks, such as grocery stores, often can be a safer place for investors to put their money. That's where Kroger comes in.

Kroger is the second-largest grocery store chain in the U.S., behind only Walmart. The company has more than 2,700 locations, 2,250 pharmacies, and 1,700 fuel locations scattered throughout 35 U.S. states and the District of Columbia.

The Cincinnati-based grocer reported $33.9 billion in sales in the second quarter, including fuel and specialty pharmacy sales. But without those items, sales were up 3.8% from last year, indicating that people are spending more money in Kroger's grocery stores.

Part of that comes from Kroger's increased emphasis on growing its own in-house brands of food products, which the company can offer at a lower price point and a greater profit than national brands.

Kroger still has a cheap valuation with a P/E ratio of 16.4, which is lower than that of Walmart (38.7), Costco Wholesale (53.5), or Sprouts Farmers Market (26.7). Coupled with a dividend yield of 2.1%, Kroger offers a compelling investment opportunity.

American Express is an advertising partner of Motley Fool Money. Bank of America is an advertising partner of Motley Fool Money. Patrick Sanders has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway, Chevron, Costco Wholesale, Jefferies Financial Group, Mastercard, Moody's, Visa, and Walmart. The Motley Fool recommends Kroger, Occidental Petroleum, and Sprouts Farmers Market. The Motley Fool has a disclosure policy.

September 26, 2025 3:15 AM EDT | Source: Questcorp Mining Inc.
Vancouver, British Columbia--(Newsfile Corp. - September 26, 2025) - Questcorp Mining Inc. (CSE: QQQ) (OTCQB: QQCMF) (FSE: D910) (the "Company" or "Questcorp") is pleased to announce that it will offer (the "Offering") up to 17,500,000 units (each, a "Unit") by way of non-brokered private placement at a price of $0.20 per Unit for gross proceeds of up to $3,500,000. Each Unit will consist of one common share of the Company (each, a "Share") and one-half-of-one share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder to acquire an additional common share of the Company at a price of $0.30 for a period of twenty-four months following closing of the Offering, subject to accelerated expiry in the event the closing price of the Shares is $0.50 or higher for ten consecutive trading days.

The Company expects to utilize the proceeds of the Offering for advancement of ongoing exploration and drill work at the La Union Gold and Silver Project, upcoming exploration work at its North Island Copper Property and for general working capital purposes.

In connection with completion of the Offering, the Company will pay finders' fees to eligible third-parties who have introduced subscribers to the Offering. All securities issued in connection with the Offering will be subject to restrictions on resale for a period of four-months-and-one-day in accordance with applicable securities laws. Completion of the Offering remains subject to receipt of regulatory approvals.

About Questcorp Mining Inc.

Questcorp Mining Inc. is engaged in the business of the acquisition and exploration of mineral properties in North America, with the objective of locating and developing economic precious and base metals properties of merit. The Company holds an option to acquire an undivided 100% interest in and to mineral claims totaling 1,168.09 hectares comprising the North Island Copper Property, on Vancouver Island, British Columbia, subject to a royalty obligation. The Company also holds an option to acquire an undivided 100% interest in and to mineral claims totaling 2,520.2 hectares comprising the La Union Project located in Sonora, Mexico, subject to a royalty obligation.

This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the intended use of proceeds from the Offering. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: the ability of Riverside to secure geophysical contractors to undertake orientation surveys and follow up detailed survey to confirm and enhance the drill targets as contemplated or at all, general business, economic, competitive, political and social uncertainties, uncertain capital markets; and delay or failure to receive board or regulatory approvals. There can be no assurance that the geophysical surveys will be completed as contemplated or at all and that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268095

By Reuters

September 26, 20257:26 AM UTCUpdated ago

A logo of BMW is seen inside a car dealer in Nijmegen, Netherlands February 26, 2025. REUTERS/Piroschka van de Wouw/File Photo Purchase Licensing Rights, opens new tab

CompaniesSept 26 (Reuters) - BMW

(BMWG.DE), opens new tab is recalling over 196,000 vehicles in the U.S. as the engine starter relay may corrode, leading to overheating and short circuit, increasing the risk of a fire, the U.S. National Highway Traffic Safety Administration said on Friday.

The issue affects multiple models including Toyota Supra and 2022 BMW 230i vehicles, the U.S. auto safety regulator said.

Sign up here.

BMW dealers will replace the engine starter, free of charge, NHTSA said in the notice.

Reporting by Ruchika Khanna in Bengaluru; Editing by Mrigank Dhaniwala

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Scan QR code to install app

Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.Risk DisclaimersThis website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.

September 26, 2025 01:00 ET

 | Source:

Addex Therapeutics

Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on October 1, 2025.

Title:   Addex Therapeutics Reports Half-Year 2025 Financial Results and Provides Corporate Update
Date: October 1, 2025
Time: 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) 

Joining the Conference Call:

Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number.
Webcast registration URL:

https://edge.media-server.com/mmc/p/vh6nhzwt

Conference call registration URL:

https://register-conf.media-server.com/register/BI403a5726888046a6a0645698cc9fdaec

About Addex Therapeutics

Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com

  Contacts: 

Addex Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPCNATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population New data for Pluvicto in prostate cancer and Kisqali in breast cancer strengthen the profiles of both medicines, with promise for new SoC in earlier disease settings Basel, September 26, 2025 – Novartis will present new data from 34 abstracts across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin (October 17-21, 2025).

“We look forward to sharing new clinical data that underscores how we are reimagining treatment for breast and prostate cancer, advancing highly effective therapies designed to improve quality of life, enable more personalized care and ultimately provide more time for cancer patients,” said Dushen Chetty, PhD, Global Head of Oncology Development, Novartis, Ad Interim. “Our ambition is to set new standards of care in some of the most prevalent cancers by pioneering novel technologies like radioligand therapy.”

Key highlights of data accepted by ESMO include:

MedicineAbstract titleAbstract Number/
Presentation Details   Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan)Phase 3 trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)#LBA6
Presidential Symposium 2 (Proffered Paper session)
October 19, 2025
16:30 – 18:15 CESTPluvicto™ (lutetium (177Lu) vipivotide tetraxetan)Associations between quantitative baseline 68Ga-PSMA-11 PET parameters and 177Lu-PSMA-617 efficacy in the PSMAfore Study#2390P
Poster Presentation
October 18, 2025
09:00 – 17:00 CESTPluvicto™ (lutetium (177Lu) vipivotide tetraxetan)Final analysis of patients treated with [177Lu]Lu-PSMA-617 in early access program in metastatic castration-resistant prostate cancer (mCRPC) in France#2389P
Poster Presentation
October 18, 2025
09:00 – 17:00 CEST[225Ac]-PSMA-617PSMAcTION trial-in-progress: a phase 2/3 randomized trial of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) versus standard of care in patients with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA therapy#2516TiP
Poster Presentation
October 18, 2025
09:00 – 17:00 CESTKisqali® (ribociclib)Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes#LBA14
Proffered Paper session
October 17, 2025
14:00 – 15:30 CESTKisqali® (ribociclib)Impact of neoadjuvant chemotherapy (NACT) response on clinical outcomes with ribociclib (RIB) in HR+/HER2− EBC: a subgroup analysis from the phase 3 NATALEE trial#366P
Poster Presentation
October 20, 2025
09:00 – 17:00 CESTKisqali® (ribociclib)A NATALEE data–based machine learning (ML) model to predict distant recurrence (DR) and treatment (tx) effect in real-world (RW) patients (pts) with HR+/HER2– early breast cancer (EBC) without CDK4/6 inhibitor (CDK4/6i) tx#372P
Poster Presentation
October 20, 2025
09:00 – 17:00 CESTKisqali® (ribociclib)Real-world characteristics, treatments and outcomes of NATALEE and monarchE-eligible HR+/HER2- early breast cancer patients in the hospital district of Helsinki and Uusimaa (HUS), Finland#360P
Poster Presentation
October 20, 2025
09:00 – 17:00 CESTKisqali® (ribociclib)Risk of Recurrence (ROR) After Neoadjuvant Ribociclib Plus ET in Clinically High-Risk ER+/HER2− BC: Preliminary Analysis of the SOLTI-RIBOLARIS Trial #296O
Proffered Paper session
October 17, 2025
14:00 – 15:30 CEST Novartis in oncology
The Novartis oncology strategy focuses on people living with cancer and those who care for them, from loved ones to clinical care teams, including their providers. For the past 30+ years, the aim has been to extend and improve lives by discovering differentiated, innovative and practice-changing medicines for patients.

As Novartis reimagines medicine, it collaborates with a wide range of patient advocacy groups and supports education, early cancer screening and diagnosis. With approximately 35 research and development projects across solid tumors, hematology and radioligand therapy (RLT), Novartis is committed to using technology, leading science and patient-centered research to deliver pioneering cancer care for all those in need.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

# # #

Novartis Media Relations
E-mail: [email protected]

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

This transcription was created from a CEF Insights podcast recorded in September 2025. For more information, please visit cefa.com. This material is not and is not intended as investment advice, an indication of trading intent or holdings or the prediction of investment performance. All fund-specific information is the latest publicly available information. All other information is current as of the date of this presentation. All opinions and forward-looking statements are subject to change at any time.
Western Asset Management disclaims any responsibility to update such views and/or information. This information is deemed to be from reliable sources; however, Western Asset does not warrant its completeness or accuracy. This presentation is not intended to, and does not constitute an offer or solicitation to sell or a solicitation of an offer to buy any security, product, investment advice or service (nor shall any security, product, investment advice or service be offered or sold) in any jurisdiction in which Western Asset is not licensed to conduct business, and/or an offer, solicitation, purchase or a sale would be unavailable or unlawful.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SummaryHubSpot remains a buy, driven by strong AI execution, rapid Core Seat adoption, and accelerating multi-hub usage.HUBS's AI strategy, including "The Loop" and Data Hub, positions customers for success in the evolving Agent Engine Optimization (AEO) landscape.The new seat-based pricing model increases user penetration and embeds HUBS deeper into organizations, fueling robust ARR growth. MoMo Productions/DigitalVision via Getty Images

Investment action I had a buy rating for HubSpot (NYSE:HUBS) previously, as I believed it was in a great position to grow robustly, with support from the shift to seat-based pricing and AI monetization. The latest updates, particularly from INBOUND 2025, reinforce my

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Crinetics Pharmaceuticals, Inc. - Special Call

Company Participants

Gayathri Diwakar - Senior Director of Investor Relations
R. Struthers - Founder, President, CEO & Director
Dana Pizzuti - Chief Medical & Development Officer
Isabel Kalofonos - Chief Commercial Officer
Tobin Schilke - Chief Financial Officer
Alan Krasner - Chief Endocrinologist

Conference Call Participants

Joshua Schimmer - Cantor Fitzgerald & Co., Research Division
Yasmeen Rahimi - Piper Sandler & Co., Research Division
Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division
Joseph Schwartz - Leerink Partners LLC, Research Division
Anthea Li - Jefferies LLC, Research Division
Catherine Okoukoni - Citizens JMP Securities, LLC, Research Division
Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division
Cory Jubinville - LifeSci Capital, LLC, Research Division
Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division
Catherine Novack - JonesTrading Institutional Services, LLC, Research Division

Presentation

Operator

Welcome to the Crinetics Pharmaceuticals PALSONIFY FDA Approval Conference Call. [Operator Instructions]

I will now turn the call over to Gayathri Diwakar, Head of Investor Relations. Please go ahead.

Gayathri Diwakar
Senior Director of Investor Relations

Thank you, operator. Good afternoon, everyone, and thank you for joining us to discuss the FDA approval of PALSONIFY. Today on the call, we have Dr. Scott Struthers, Founder and Chief Executive Officer; Dr. Dana Pizzuti, Chief Medical and Development Officer; and Isabel Kalofonos, Chief Commercial Officer. In addition, Tobin Schilke, Chief Financial Officer; and Dr. Alan Krasner, Chief Endocrinologist, will also be joining for the Q&A portion.

Please note, there is a slide deck for today's presentation, which is in the Events and Presentations section of the Investors page on the Crinetics website. In addition, a press release was issued earlier today and is also available on the corporate website.

Slide 2. As a reminder, we'll be making forward-looking statements, and I invite you to learn more about the risks and uncertainties associated with these

Recommended For You

September 26, 2025 02:00 ET

 | Source:

Norsk Hydro

Hydro's third quarter results 2025 will be released at 07:00 CEST (01:00 EDT, 06:00 BST, 05:00 UTC/GMT) on October 24, 2025. The quarterly report and presentation will be available on hydro.com at the same time as the release.  

President and CEO Eivind Kallevik and Executive Vice President and CFO Trond Olaf Christophersen, will host a webinar in English at 08:30 CEST the same day. There will be a Q&A session directly after the presentation. There will be no physical presentation or press conference.  

To join the webinar and ask questions, use the link to the webcast page.  

The webcast is powered by Zoom. No login or registration in advance is required. It is also possible to log in using the dial-in option:  

Norway +47 2400 4736 

London, UK +44 330 088 5830 

New York, US +1 929 205 6099 

Find your local number 

Meeting ID: 933 0129 2025

We advise you to investigate in advance if your company has any restrictions using the Zoom platform. 

Investor contact: 

Martine Rambøl Hagen 
+47 91708918 
[email protected] 

, /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN), China's leading used car retailer, today announced that its new used car superstore in Zhengzhou, Henan Province will officially open on September 27, 2025.

The Zhengzhou used car superstore has a gross floor area of approximately 150,000 square meters, integrating one of China's largest used-car showrooms with an in-house reconditioning facility. The site is designed to accommodate up to 5,000 vehicles for display and sale. Following the Company's successful launch of superstores in Xi'an, Hefei, and Wuhan, Zhengzhou marks Uxin's fourth superstore, underscoring the Company's ability to replicate and scale its business model across major Chinese cities.

Zhengzhou is the capital city of Henan Province, which is one of China's most populous provinces. The city has a resident population exceeding 13 million and over 5 million registered vehicles. Zhengzhou ranks among the top ten cities nationwide in used car transactions and serves as the key transportation hub in central China, providing strong fundamentals to support the operation of a large-scale used car superstore.

With the opening of the Zhengzhou superstore, Uxin is set to deliver a wider selection of high-quality vehicles and professional services to regional consumers, while significantly expanding its market penetration in central China. The continued rollout of new superstores is expected to be a key growth driver of Uxin's sales volume and financial performance in the coming years.

About Uxin
Uxin is China's leading used car retailer, pioneering industry transformation with advanced production, new retail experiences, and digital empowerment. We offer high-quality and value-for-money vehicles as well as superior after-sales services through a reliable, one-stop, and hassle-free transaction experience. Under our omni-channel strategy, we are able to leverage our pioneering online platform to serve customers nationwide and establish market leadership in selected regions through offline superstores with inventory capacities ranging from 2,000 to 8,000 vehicles. Leveraging our extensive industry data and continuous technology innovation throughout more than ten years of operation, we have established strong used car management and operation capabilities. We are committed to upholding our customer-centric approach and driving the healthy development of China's used car industry.

Safe Harbor Statement
This press release contains statements that may constitute "forward-looking" statements which are made pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to," and similar statements. Statements that are not historical facts, including statements about Uxin's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the risk and uncertainties as to the timing of the entry into definitive agreements or consummation of the transactions; the risk that certain closing conditions of the transactions may not be satisfied on a timely basis, or at all; impact of the COVID-19 pandemic; Uxin's goal and strategies; its expansion plans and successful completion of certain financing transactions; its future business development, financial condition and results of operations; Uxin's expectations regarding demand for, and market acceptance of, its services; its ability to provide differentiated and superior customer experience, maintain and enhance customer trust in its platform, and assess and mitigate various risks, including credit; its expectations regarding maintaining and expanding its relationships with business partners, including financing partners; trends and competition in China's used car e-commerce industry; the laws and regulations relating to Uxin's industry; the general economic and business conditions; and assumptions underlying or related to any of the foregoing.

For investor and media enquiries, please contact:
Uxin Limited Investor Relations
Uxin Limited
Email: [email protected] 

The Blueshirt Group
Mr. Jack Wang
Phone: +86 166-0115-0429
Email: [email protected] 

SOURCE Uxin Limited

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Commerzbank share price has pulled back from its highest point this year as investors wait for more information from UniCredit. The CBK stock was trading at €32.7 on Friday, down from the year-to-date high of €38.3.

Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) has struck a five-year supply agreement with a UK bus manufacturer that will see its driver monitoring technology installed on thousands of vehicles across Europe, ahead of the introduction of stricter safety rules.

The London-listed company, which develops artificial intelligence systems to track driver alertness, said its Guardian Generation 3 system will be fitted at the factory on new buses destined for European markets.

The tie-up builds on around 200 vehicles the bus maker has already fitted with the kit. The manufacturer produces more than 1,700 buses a year.

The move comes as the European Union prepares to enforce its General Safety Regulation. From July 2026, new buses, lorries and other heavy vehicles will need to include technology to detect driver distraction and warn of potential accidents.

Seeing Machines is also working with four other vehicle makers in Europe on regulatory approvals, known as homologation, that could cover more than 4,000 vehicles a year.

Homologation is the process by which a vehicle is certified to meet the required safety standards across an entire model range.

Beyond bus manufacturing, the company is advancing talks with a large oil and gas operator on a contract to expand Guardian across its European fleet. The system is already in use with this customer in the UK and four other European countries.

Paul McGlone, chief executive of Seeing Machines, said: “This agreement is a major step for Seeing Machines as we expand our Guardian Generation 3 technology across Europe, supporting our partners to meet the highest safety standards ahead of the GSR deadline.

"Our growing collaborations with OEMs and industry leaders not only demonstrate the value of our AI-powered safety technology but also reflect Europe's strong commitment to protecting road users.”

, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW).

If you currently own shares of Edwards stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=29704 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:                                     

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY  10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Pennon Group PLC (LSE:PNN, OTC:PEGRY) has reported a strong start to its 2026 financial year, with profitability returning and EBITDA expected to increase by about 60% year on year. In a trading statement, the water utility company said it remains on track to deliver its 7% rate of return on equity (RORE) target, supported by efficient financing and programme efficiencies.

Chief executive Susan Davy said: "We're driving real improvements for our customers and communities whilst delivering a return to strong profitability. Despite the pressures of a hot summer, we've maintained resilient water supplies and continued to improve services for our customers. Whilst there is more to do, our pollution reduction plans are delivering tangible benefits, halving the number of pollutions and spills from storm overflows, reducing our impact on the environment."

The group highlighted that pollution incidents and storm overflow spills had halved year-on-year, supported by investments in wastewater networks and reduced rainfall. In water services, performance was impacted by supply interruptions from a burst main, although resources benefited from resilience measures put in place after the 2022 drought.

Pennon also strengthened its liquidity by raising £300 million under its Euro Medium Term Notes (EMTN) programme. Construction is progressing across Pennon Power's projects, with two sites in Scotland set to be connected to the Grid in October. When fully operational by FY27, the renewable energy portfolio will generate the equivalent of 40% of group consumption.

Following the planned retirement of Davy, the board has begun the search process for a new chief executive. Half-year results will be announced on 27 November 2025.

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo Purchase Licensing Rights, opens new tab

ZURICH, Sept 26 (Reuters) - Switzerland's Roche on Friday pointed to the fact that one of its U.S. units broke ground on a new facility in August and that the pharma company had pledged major U.S. investments after President Donald Trump's latest tariff announcement.

Trump said on Thursday the United States will impose a 100% tariff on imports of branded or patented pharmaceutical products from October 1, unless a pharmaceutical company is building a manufacturing plant in the U.S.

Sign up here.

A Roche spokesperson pointed to the August 25 announcement about its Genentech unit's plans for the facility in Holly Springs, North Carolina as well as Roche's $50 billion pledge to invest in U.S. manufacturing and research and development.

Roche

(ROG.S), opens new tab and Novartis

(NOVN.S), opens new tab are Switzerland's two biggest pharmaceutical companies with major U.S. production operations. Novartis, which also made a large U.S. investment pledge earlier this year, did not immediately reply to a request for comment.

An industry source estimated that based on the initial U.S. indications, the tariffs as set out by Trump on Thursday would probably not apply to the two firms.

Reporting by Paul Arnold, Editing by Friederike Heine

Our Standards: The Thomson Reuters Trust Principles., opens new tab

, /PRNewswire/ -- Boeing [NYSE: BA] and Turkish Airlines announced today a firm order for up to 75 787 Dreamliners, the flag carrier's largest ever Boeing widebody purchase. The deal includes 35 of the 787-9 model, 15 of the larger 787-10, and options for 25 787 Dreamliners to grow and modernize the airline's fleet. The new order will support more than 123,000 jobs across the U.S.

Turkish Airlines orders up to 75 Boeing 787 Dreamliners, and commits to more 737 MAX jets.

The airline also announced its intent to purchase up to 150 more 737 MAX airplanes, which will be its largest Boeing single-aisle order when finalized. The 787 and 737 MAX orders combined will double Turkish Airlines' Boeing fleet as the carrier expands its capacity and network.

"This landmark agreement represents much more than a fleet growth. It is a reflection of our leadership in the industry as well as our dedication to innovation and operational excellence," said Prof. Ahmet Bolat, Turkish Airlines Chairman of the Board and the Executive Committee. "The addition of these advanced Boeing aircraft to our fleet will not only enhance our operational capabilities but also become a significant element supporting Turkish Airlines' 2033 Vision of expanding our fleet to 800 aircraft."

Across a network that reaches the most countries of any airline in the world, Turkish Airlines operates more than 200 Boeing jets today, including the 787-9, 777, 737 MAX, Next-Generation 737 and 777 Freighter airplanes.

Adding the larger 787-10 to its future fleet will enable Turkish Airlines to benefit from additional passenger and cargo capacity while improving fuel efficiency on high-demand routes between Istanbul and destinations in the U.S., Africa, Southeast Asia and the Middle East.

The 787-10, like the 787-9, also offers superior passenger comfort with the largest windows of any widebody jet, air that is less dry and pressurized at a lower cabin altitude, and technology that senses and counters turbulence for a smoother ride.

"We are honored that Turkish Airlines has once again chosen the 787 Dreamliner and 737 MAX to power its future growth," said Stephanie Pope, president and CEO of Boeing Commercial Airplanes.

Turkish Airlines is one of the global operators that have made the 787 a versatile component of their long-haul fleets. With more than 1,200 airplanes delivered, the 787 Dreamliner family serves about 500,000 passengers daily and connects the most countries of any widebody fleet.

Pope added, "As a proud partner to Türkiye and the Turkish aviation industry for 80 years, we look forward to continuing our support of Turkish Airlines as they expand operations and deliver exceptional experiences to their passengers."

For eight decades, Boeing has supported Türkiye's airline operators with commercial jets and services, as well as the government with defense platforms.

With offices in Ankara and Istanbul, Boeing has invested $2 billion in supply chain development, creating nearly 5,000 jobs in Türkiye. These investments foster growth in the local aerospace sector, promote innovation, and enhance the integration of Turkish industry into the global aerospace supply chain through its supplier development program.

A leading global aerospace company and top U.S. exporter, Boeing develops, manufactures and services commercial airplanes, defense products and space systems for customers in more than 150 countries. Our U.S. and global workforce and supplier base drive innovation, economic opportunity, sustainability and community impact. Boeing is committed to fostering a culture based on our core values of safety, quality and integrity.

Contact
Boeing Media Relations
[email protected]

SOURCE Boeing

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

AlphaTON has made its first buy of $30 million of Toncoin for its new treasury strategy. It comes shortly after the company closed a strong $71 million funding round for future TON purchases.

AlphaTON Commits $30M to Treasury Holdings
In a recent press release, AlphaTON,  a Nasdaq-listed firm dedicated to the Telegram ecosystem, confirmed that it has acquired approximately $30 million worth of TON following the close of $71 million in combined financing. The package included a $36.2 million private placement and a $35 million loan facility secured through BitGo Prime.

This purchase immediately positions the firm among the largest holders of the token globally. It also marked the company’s first major treasury transaction. The company also plans to expand its reserves to $100 million by the end of 2025. Additionally, this move would provide shareholders with institutional-grade exposure to Telegram’s billion-user ecosystem.

CEO Brittany Kaiser described the development as an opportunity for the company to invest in an infrastructure that will power decentralized applications across the Telegram network.

“Today marks a pivotal moment in AlphaTON Capital’s journey as we officially establish ourselves as a premier digital asset treasury company with substantial TON holdings,” she said. “These successful financings and immediate deployment…positions us to be a driving force in the next wave of decentralized application development”

This purchase comes shortly after the company launched its Toncoin treasury in the first week of the month. The firm rebranded from Portage Biotech to AlphaTON, aligning its corporate identity with its Toncoin-focused strategy. 

Enzo Villani, the company’s Executive Chairman and Chief Investment Officer, noted that the treasury initiative marks only the beginning of the company’s strategy. He clarified that by investing capital straight into the token, the company is positioned to take the lead in staking, validation, and ecosystem expansion as a whole.

Toncoin Treasury Momentum Builds
The firm’s move reflects a broader trend among treasury companies to increase their exposure to the token. In July, in collaboration with Kingsway Capital Partners, the TON Foundation launched a public vehicle dedicated to accumulating Toncoin, aiming to raise up to $400 million in funding.

Other firms are also following suit. Verb Technology, now known as TON Strategy, disclosed treasury assets worth $780 million earlier this year. This includes $713 million in the token alongside $67 million in cash reserves. The company approved a $250 million plan to buy back its own stock. This move aims to strengthen its balance sheet and create more value for shareholders.

These actions show that institutions are becoming more confident in the token’s ability to serve as a bridge between social media adoption and blockchain technology.

With AlphaTON’s financing round now complete, the firm outlined its growth strategy plans. The company plans to leverage its holdings for network validation and staking, generating predictable yield streams. They would also direct resources toward supporting decentralized applications built on the Telegram mini app ecosystem. 

It is also worth mentioning that the company is backed by stakeholders such as Animoca Brands, Kraken, SkyBridge Capital, and DWF Labs. The company has pledged to keep investors informed through regular treasury and operational updates in the months ahead.

Investment disclaimer: The content reflects the author’s personal views and current market conditions. Please conduct your own research before investing in cryptocurrencies, as neither the author nor the publication is responsible for any financial losses.

Ad Disclosure: This site may feature sponsored content and affiliate links. All advertisements are clearly labeled, and ad partners have no influence over our editorial content.

A cryptocurrency analyst has explained how a Chainlink triangle breakout setup could point to a massive $100 target for the asset’s price.

Chainlink Is Coiling Inside A Triangle Right Now
In a new post on X, analyst Ali Martinez has talked about a triangle pattern forming in the weekly price of Chainlink. Triangles refer to consolidation channels from technical analysis (TA) that involve an asset trading between two converging trendlines.

Like any other consolidation channel, the upper trendline acts a source of resistance, while the lower one that of support. In other words, tops can be likely to occur on retests of the former and bottoms at the latter.

There are a few different types of triangles, with some of the popular ones being the ascending, descending, and symmetrical variations. The orientation of the trendlines decides which type a particular triangle falls into.

Ascending and descending triangles have one trendline parallel to the time-axis: upper line in the former and lower one in the latter. Symmetrical triangles lie between the two, having both lines at a roughly equal and opposite slope.

Chainlink has potentially been trading inside a triangle over the last few years, but as the below chart shared by Martinez shows, this particular triangle doesn’t cleanly fit into any of these types.

Looks like the 1-week price of the coin has been trading near the upper boundary of the triangle | Source: @ali_charts on X
From the graph, it’s visible that Chainlink’s triangle lies is angled upward, but not fully, so it lies somewhere between a symmetrical triangle and an ascending one.

LINK made a retest of the upper line of the pattern earlier in the year and ended up finding rejection. The cryptocurrency is now on the way down, but the analyst thinks an extended drawdown may not actually be so bad.

“A dip to $16 on Chainlink $LINK would be a gift,” says Martinez. This price is where the 0.5 Fibonacci level lies. Fibonacci Extension/Retracement levels are lines drawn using ratios derived from the famous Fibonacci series.

The analyst has taken LINK’s top and bottom from the last few years as the 1 and 0 levels, respectively, and has drawn retracement levels between them. The $16 mark happens to be where one such key retracement level lies.

Martinez has highlighted in the chart what path the asset could end up following if it bounces off this level. It would appear that in the analyst’s view, a rebound from the line could end up leading to a breakout from the triangle and set a potential target at the 1.272 extension level, drawn up from the 1 level (top). In Chainlink price terms, this level corresponds to almost $100.

It now remains to be seen whether LINK will break out of the triangle in the near future, and whether a setup similar to the analyst’s would play out.

LINK Price
At the time of writing, Chainlink is floating around $20.25, down over 17% in the last seven days.

The price of the coin appears to have plummeted over the last few days | Source: LINKUSDT on TradingView
Featured image from Dall-E, charts from TradingView.com

Dogecoin price has crashed below an important level this week as liquidations jumped and the Crypto Fear and Greed Index sank into the fear zone. This article provides a DOGE price forecast as a risky pattern forms despite the ongoing DOJE ETF inflows.

TLDR:

AlphaTON Capital raised $71M through a share sale and credit facility to accelerate its TON-focused growth plan.
The company acquired $30M worth of TON tokens, becoming one of the largest holders in the Telegram ecosystem.
Leadership aims to scale TON treasury to $100M by Q4 2025 and expand network validation operations.
AlphaTON plans to invest in Telegram mini apps and DeFi projects to support ecosystem adoption.

Crypto investors now have another reason to watch the Telegram ecosystem closely. AlphaTON Capital has secured fresh funding and is stacking TON at scale. The company says its new position will let it shape the next wave of Telegram-based apps. 

Executives are betting big on TON’s future and plan to grow their holdings even more this year. This could set up a powerful play for treasury-backed growth in 2025.

According to a press release, AlphaTON Capital closed $71 million in financing through a mix of share sales and a $35 million credit line with BitGo Prime. The funds were immediately used to acquire $30 million worth of TON tokens, making AlphaTON one of the largest holders in the network.

The deal strengthens the company’s balance sheet and gives its investors direct exposure to the Telegram-linked blockchain. Executives say this first tranche sets the stage for a $100 million treasury goal by the end of 2025.

CEO Brittany Kaiser explained that the company is building more than just a reserve. She said their focus is on staking, validation, and seeding early Telegram mini apps that could reach millions of users.

Enzo Villani, Executive Chairman, said the financing positions AlphaTON at the intersection of social media and blockchain adoption. He expects staking operations to begin soon, generating predictable yield for the treasury.

TON Treasury Growth and Ecosystem Strategy
AlphaTON plans to scale its treasury through ongoing TON acquisitions and yield generation. The company says it will use validation rewards to reinvest in the ecosystem and back promising projects.

This includes scouting opportunities in Telegram mini apps, DeFi protocols, and infrastructure tools built on TON. The strategy is designed to capture value at multiple layers of the network.

The leadership team includes industry veterans from Nasdaq Global Corporate Solutions, SkyBridge Capital, and RSV Capital, which they say gives them a competitive edge in executing their growth plan.

The company expects to provide further updates on treasury expansion and early ecosystem investments in the coming months. Investors watching the TON price may look for signs of market reaction as AlphaTON grows its holdings.